You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Norovirus travel study: data collection event summary

From: Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler’s diarrhea: a prospective cohort study protocol

Content Data Collection Event
Pre-Travel Peri-Travel Post-Travel
Recruitment Baseline Clinical Samplea Daily Diary Diary Day 2 Diary Day 7 Diary Day 14 Clinical Sampleb,c 3 Month Follow-Upc 6 Month Follow-Upc
Eligibility          
Demographics          
Travel
 Plans/Itinerary        
 Type/Reason for Travel           
 Behavior/Activities          
 Past 3 Months         
Health Information
 Blood Type           
 Pre-Existing Condition           
 Regular Bowel Patterns         
 Non-Specific Symptoms      
 Illness in Week Prior to Travel*           
Medication/Vaccination
 Medications      
 Vaccinations        
Acute Gastroenteritis      
 Week Prior to Travel*           
 Medical Care      
 Direct and Indirect Costs        
 Impact on Daily Function       
 Impact on Travel Plans / Planned Activities         
Travel Companion and Household Illness           
New Onset Conditions / Potential Post-Infectious Sequelae         
 Medical Care         
 Direct and Indirect Costs         
 Impact on Daily Function         
Self-Collected Stool           
  1. aPre-travel clinical sample provided within 7 days of travel start
  2. bPost-travel clinical sample provided within 14 days of symptom onset if traveler experienced acute gastroenteritis between day 2 of travel and day 2 post-travel or within 14 days of travel return if traveler was selected at study enrollment to provide a post-travel stool sample regardless of the absence of acute gastroenteritis symptoms while traveling
  3. cData collection event for a subset of the study participants including those with acute gastroenteritis between day 2 of travel and day 2 post-travel or 25% of study participants selected at enrollment to provide post-travel stool samples and extended 3 and 6-month follow-up